Three Cases of Cutaneous Albinism: Report of a Case Treated with Photodynamic Therapy

Three cases of cutaneous albinism (OCA) treated with photodynamic therapy (PDT) are presented. OCA is characterized by the complete lack of melanin in the skin, hair, and eyes. The most severe phenotype of OCA is OCA4, which is caused by mutations in the gene encoding tyrosinase, the rate-limiting enzyme in melanin biosynthesis.

The treatment of OCA typically involves photodynamic therapy, which involves the use of a photosensitizer (e.g., 5-aminolevulinic acid or methyl-aminolevulinic acid) and a near-infrared light source. The photosensitizer is activated by the light, leading to the production of singlet oxygen and other reactive oxygen species that damage the underlying tissue.

In the three cases presented, the patients were treated with DL-PDT (5-aminolevulinic acid and 720-nm light) and their response was monitored using ultrasound imaging. The results showed a significant decrease in the size and number of lesions, as well as improved pigmentation in the treated areas.

References


Conflicts of Interest

The authors declare that they have no conflicts of interest.
three female patients, aged 22, 48 and 65 years old. The use of DL-PDT in patients with OCAs was approved by the local ethics committee.

On the day of the procedure, after the curettage of facial AK lesions, a chemical filter with sun protection factor (SPF) 50 plus lotion (Actinica®, Galderma, France) was applied on the face and other exposed areas. Subsequently, approximately 1 g of the 16% MAL cream (Metvix®, Galderma, France) was applied throughout the face, and patients stayed outdoors, in the shade, between 7:30 and 9:30 AM. After that, the MAL cream was removed, and patients were discharged, with the instruction to strictly maintain the use of sunscreen at home. AK lesions were counted before the session and after 4, 12 and 24 weeks of follow-up. The patients were also assessed, after 2 hours of exposure, for the occurrence and grade of local skin reactions.

A total of 66 facial AK lesions were treated in the three patients, all of whom completed the 24-week period of follow-up. Of the 66 treated lesions, 52 lesions (78.8%) were considered as clinically cured at weeks 4 and 12, and 50 lesions (75.8%) were considered as cured at week 24 (Figures 1 to 3). No pain or burning sensation was reported by any of the patients during the 2-hour shade period. The 22-year-old patient was the only one who presented moderate facial erythema immediate after the procedure, with

---

**Figure 1** Clinical improvement after 6 months of DL-PDT.

**Figure 2** Field cancerization of the skin before and 6 months after DL-PDT session.
mild pruritus during outdoor exposure (Figure 4). However, she reported being exposed to the sun for about 10 minutes during the 2-hour period with MAL cream. None of the three patients had adverse effects at the 4-week follow-up visit.

In the current study, we found that nearly 76% of the treated AK lesions could be considered cured after 6 months of follow-up. This cure rate is within the range found in the major European5 and Australian7 multicenter studies of DL-PDT. Since patients with OCA present with extensive AK, with a large number of lesions at an early age, it is important to develop alternative treatments that rapidly eliminate the lesions in large areas and with little local reaction.

During DL-PDT, avoidance of exposure to direct UV radiation through permanence in the shade during the whole period of 2 hours is fundamental in patients with OCA. We observed moderate erythema immediately after the procedure in one of the patients, who, despite orientation, was exposed to sunlight for about 10 minutes. The city of Fortaleza is located at a low latitude (03°43′02″ South), with average annual temperature of 26.3 °C. Such warm and sunny weather characteristics allow the use of DL-PDT throughout the year. On the other hand, patients with OCA undergoing DL-PDT in places with similar characteristics have to be carefully instructed about the procedure. Moreover, the use of SPF50 clothing and sunscreen is recommended during the 2-hour exposure in the shade. In our three patients, DL-PDT sessions were scheduled and performed early in the morning, with no overcast or rainy weather.

In conclusion, DL-PDT may be an option in the treatment of multiple lesions of AK on the face of patients with OCA. One of the advantages of treating a wide area such as the face in a single day is the ability to maintain the daily activities of these patients, especially when compared with treatments that require a length of time at home and which may cause skin reactions, both of which can impair adherence to treatment.

References

4. Wiegell SR, Haedersdal M, Philipsen PA, Eriksen P, Enk CD, Wulf HC. Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy.

Figure 3 Treatment area before and after 24 weeks of follow up.

Figure 4 Moderate facial erythema immediately after the 2-hour outdoor exposition.


L.E. Garcia Galvão,* R. Tomaz, H. de Sá Gonçalves
Centro de Dermatologia «Dona Libânia», Fortaleza, Brasil
*Corresponding author.
E-mail address: lgalvao@dermatologista.com.br

© 2018 Elsevier España, S.L.U. and AEDV. Published by Elsevier España, S.L.U. All rights reserved.

Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab

Brote de psoriasis en placas y edema periférico en un paciente tratado con atezolizumab

To the Editor:

A 75-year-old man was referred to the dermatology clinic for evaluation of skin lesions after receiving his first dose of atezolizumab (1200mg) for treatment of poorly differentiated stage IV urothelial carcinoma of the prostatic urethra (metastasis to the lungs, liver, bone, and lymph nodes). Twelve months previously, the patient had completed systemic treatment with chemotherapy (cisplatin 75mg/m² day 1 + gemcitabine 1250mg/m² on days 1 and 8 and every 21 days) in 4 cycles. No clinical or radiological response was observed, and the treatment was poorly tolerated (asthenia, vomiting, and moderate kidney failure). He had a 42-year history of mild psoriasis affecting the elbows and knees.

Twelve days after the first infusion of atezolizumab, his existing lesions began to worsen, and new lesions began to appear on the extensor aspects of both limbs and the trunk. These were intensely pruritic and compatible with a clinical diagnosis of psoriasis (Psoriasis Area Severity Index = 12, body surface area affected = 6, visual analog scale for itching = 10). These findings were accompanied by distal edema affecting both lower limbs. The patient was prescribed oral prednisone 30mg for 7 days to be tapered by 10mg every week, bilastine 20mg every 12 hours, and topical treatment with clobetasol propionate 0.1% cream every 12 hours for 15 days. His lesions resolved in 3 weeks, and no residual lesions were observed. Atezolizumab was discontinued because of the skin toxicity. Given the patient’s poor general status, he refused all cancer medication and is currently receiving palliative care. He was diagnosed with probable adverse reaction to atezolizumab (Naranjo algorithm, 6 points).

Programmed death 1 (PD-1) is a key immune checkpoint receptor that is expressed on T cells and functions mainly in peripheral tissue.1 Atezolizumab is the first PD ligand 1 (PD-L1) inhibitor approved by the United States Food and Drug Administration. This human immunoglobulin G1 monoclonal antibody binds selectively to PD-L1 and prevents interaction with PD-1 and B7-1 (also known as CD80), while sparing the interaction between PD ligand 2 (PD-L2) and PD-1.2 When PD-1 is activated, the immune system is inhibited, thus enabling tumor growth. In their various indications for different cancers, new anti-PD-1 drugs (nivolumab, pembrolizumab, pidilizumab) and anti–PD-L1 drugs (atezolizumab and durvalumab) curb this inhibition by enabling the immune system to control tumor progression.3

There have been various reports of adverse reactions to PD-1 and PD-L1 inhibitors in up to 50% of patients. These were mainly cutaneous (lichenoid reactions, eczema, vitiligo, and pruritus) and mild and did not require treatment to be discontinued.3,4 However, other authors report these inflammatory reactions to be severe, requiring treatment with oral corticosteroids, and highlight an objective antitumor response.5 One group of cutaneous reactions to this drug are those based on neutrophils, which, owing to their increased count in the skin, cause Sweet syndrome, acute generalized exanthematous pustulosis, intracorneal pustular drug eruption, and psoriasis.6 Other, less common cutaneous adverse reactions include actinic keratosis, squamous cell carcinoma, and seborrheic keratosis.3 Peripheral edema is an adverse reaction that affects 10% of patients receiving treatment with atezolizumab.7

Cases of psoriasis triggered or exacerbated by this drug family are starting to be reported, although the condition

---